The results of a prospective phase 3 clinical trial, BEACON CRC, involving patients with metastatic colorectal cancer led to FDA’s approval of dual therapy with anti-EGFR and a BRAF inhibitor (cetuximab + encorafenib) [22]. This evidence concerns the gene BRAF and colorectal carcinoma.